Get started
ESPERION THERAPEUTICS INC COM USD0.001ESPERION THERAPEUTICS INC COM USD0.001ESPERION THERAPEUTICS INC COM USD0.001

ESPERION THERAPEUTICS INC COM USD0.001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0IIM trade ideas

ESPR BULLISHEsperion Therapeutics (NASDAQ: ESPR), priced at $1.68 as of September 27, focuses on creating medications for cardiovascular and cardiometabolic diseases. They've launched products like NEXLETOL and NEXLIZET, which help lower LDL cholesterol in adults. Recently, 26 hedge funds held about $98.59 million in the company, with Millennium Management as the top shareholder. Esperion reported a huge revenue jump in Q2, hitting $73.8 million—up 186% from last year—and they’re on track for continued growth, even as they manage expenses. While ESPR shows promise, we think AI stocks might offer even better returns. TARGET $2.70+
NASDAQ:ESPRLong
by SPYDERMARKET
ESPR - Momentum Biotech PlayEsperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. Disclaimer: This content is for informational purposes only and should not be considered financial advice. Recent Activities: May 22, 2024: First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and its combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), approved in Europe to treat hypercholesterolemia and significantly reduce cardiovascular risk. Block and Insider Buys: A few notable transactions observed recently. Trading Volume: Significant increase in trading volume. Investment Snapshot (As of June 7, 2024): Relative Volume: 1.82 Shares in Circulation: 154.69 million Short Float: 16.10% Key Technical Levels: 2.80 - 3.00 Zone: Highly important due to strong resistance levels. Conservative traders might want to wait for a break above this zone and closely watch price action thereafter. Resistance Points: $2.80 - $3.00: Initial resistance zone. $3.30, $3.60, $3.80: Monitor these levels; surpassing them could indicate a positive trend. Taking profits at these stages may help in realizing gains. Trading Strategy: Take Profit (TP): Aim for a target profit of $3.50, with a possibility of reaching up to $4.50. Stop Loss (SL): Establish a stop loss below $2.50 to mitigate potential losses. Chart Analysis: Refer to the attached chart for a detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
NASDAQ:ESPRLong
by meitshels_smell_trades
ESPR - Approval of NEXLETOL (Cardiovascular Diseases)Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. This is not a financial advice! 03/22/24 U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use We haven't really seen a big push of the stock price of this news yet. Recent block buys Short Float 10.06% We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. We need to break and stay above 2.6-2.7 area before entering a trade. Keep an eye on 3.0 level, needs to get broken for a further upmove. You can take partial profits at this level if u want to lock in gains. SL under 1.9 TPs approx. 4.4 or even 5.2 Most info on the chart. Trade carefully!
NASDAQ:ESPRLong
by meitshels_smell_trades
3
ESPR a penny and medtech stock LONGESPR on the 120-minute chart is surging with momentum from an FDA approval for a new cholestrol and lipid medication which will be an alternative to the at statin class which has side effects and can cause diabetes. I am familar with a few of the professionals on the science advisory board they are researchers and academics of the highest claiber. The chart shows price testing and getting support from the mean VWAP and a little bit of resistance from the first upper VWAP line. I have added to my existing position at the consolidation at VWAP. I am well informed on ESPR market prospects; this could be disruptive. The dual time frame RSI of Chris Moody has curled up and validates the idea. My interim target is the double top of this past winter. I do expect increasing volume in time with the price action that follows. Disclaimer This a hot penny stock highly volatile - you could lose on this trade. Do not trade with money you cannot afford to lose. You must manage the trade well to realize profit. There are options if the put to call ratio is rising big money is pushing a reversal
NASDAQ:ESPRLong
by AwesomeAvani
$ESPR Esperion Therapeutics Inc. NASDAQ:ESPR Esperion Therapeutics Inc. Long term PTs 39 - 53 - 76 and higher Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
NASDAQ:ESPRLong
by BADQOMOCAWGOWLD
Preparing for Earnings Season: ESPRStocks that are reporting earnings in 3 to 4 weeks can be monitored for pre-earnings runs. ESPR had momentum runs recently, as marked by the candlestick patterns within the green rectangles in this chart. A shift of sentiment can be seen in the bottoming pattern with Accumulation/Distribution indicators (the area between the blue rectangles). Often, when an earnings report is going to be great, then the company tries to leak it out subtly. IF earnings were to be negative or below expectations, then CEOs would be warning. No need to go looking for analyst recommendations, everything you need is in the charts. Focusing on the charts, rather than on the commentary around the market, will help you find the stocks that will be lucrative for trading this earnings season.
NASDAQ:ESPRLong
by MarthaStokesCMT-TechniTrader
Esperion Therapeutics On the above 3-week chart price action for Esperion Therapeutics has collapsed over 90% since the sell signal in early 2018. Now is an excellent moment to be dollar cost averaging into a long position. Why? 1) A fantastic ‘buy’ signal. Remember this is a 3-week chart. Very powerful on this scale, look left. 2) Long term price action and RSI resistance breakouts. 3) The downtrend channel confirmed support. Look left. Expect price action to now continue until the upper channel resistance. Is it possible price action falls? Sure, especially in the near term. Is it probable? No. Ww Questions? Just ask below, I'm not invested nor trading this. Type: Investment - Long anything below $7 and not before Risk: <=6% of portfolio Timeframe: 16 - 20 months Return: 3x so far since support confirmation. Target $20-24
NASDAQ:ESPRLong
by without_worries
15
short sellers will hurt bad in this one!Market Cap: 370 M Shares Outstanding: 28.2M Average Trading Volume (10 days): 451K Shares Short: 28 M Short Interest(%): 31.4% Days to cover: 15.4 Change in Short Interest: -35 Ownership Breakdown: Institutions: 93.1% General Public: Hedge Funds: 5.6% Individual insiders: 1.3% Sum: 100% Option profile: Total OI: Put Call Ratio:0.63 Put OI: Call OI: Highest Put:20 Highest Call:17.5 Max Pain: 17.5 Open Int (30-Day): 20.3K With zero general public ownership, this will be a battle of hedge funds when they want to cover their shorts..! I wonder how they will cover the 30% short interest when 93.1% belongs to institutions???
NASDAQ:ESPRLong
by Moshkelgosha
3
$ESPR Short squeeze - 1 D Candle I think ESPR could start to get interested in this level . - After a long decline from the peak ($ 40) this year, on 27/1/2021, we are now witnessing a consolidation in the price level. - I do not look at fundamental information, only technical data . Indicators : * EMA21 is the purple line * EMA9 is the green line * Consolidation at Slow Stochastic * RSI begins to change direction - 26.23M short float (low float) - Setup: Falling Wedge - Short floating percentage 32.48% - Above the consolidation at 15$ squeeze can happen * It can be very aggressive .. think of all the Short's sellers who will have to cover positions after they see a price level break after consolidation ... * No financial advice just my personal opinion, make your own DD!
NASDAQ:ESPRLong
by SaTLla101
ESPR Technical Analysis 🧙Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ESPRLong
by unfair_advantage